Expert Opin Investig Drugs. 2011 May;20(5):591-4. doi: 10.1517/13543784.2011.571202.
Epithelial ovarian carcinoma (EOC) is the most important cause of gynecological cancer-related mortality in Western societies. The majority of patients with ovarian cancer present with advanced disease, and in this group of patients, the median survival time is only 3 years. New treatment approaches are, therefore, required to improve outcome in this disease. Two strategies have emerged with promising results: poly ADP-ribose polymerase enzyme (PARP) inhibitors and targeting angiogenesis. The challenge remains to develop a convenient and accurate method to identify patients likely to benefit from targeted therapy.
上皮性卵巢癌（EOC）是西方社会妇科癌症相关死亡的主要原因。大多数卵巢癌患者就诊时已处于晚期，在这组患者中，中位生存时间仅为 3 年。因此，需要新的治疗方法来改善这种疾病的预后。已经出现了两种有前途的策略：聚 ADP-核糖聚合酶酶（PARP）抑制剂和靶向血管生成。目前的挑战仍然是开发一种方便和准确的方法来识别可能从靶向治疗中获益的患者。
